DBV Technologies announces filing of 2024 Annual Report on Form 10-K and Universal Registration Document
Châtillon, France, April 11, 2025 DBV Technologies announces filing of 2024 Annual…
Phase III Study Shows Xolair May Be More Effective With Fewer Side Effects Than Oral Immunotherapy for the Treatment of Food Allergies
– First-ever head-to-head trial comparing Xolair and oral immunotherapy (OIT) – –…
